Agilent Technologies Reports Its PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark Approval As Companion Diagnostic Test In Advanced, Metastatic Gastric, Gastroesophageal Junction Or Esophageal Adenocarcinoma
Agilent Technologies Inc. (NYSE:A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or